Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin

PURPOSE: To assess the safety of inactivated coronavirus 2019 disease (COVID-19) vaccine in tuberous sclerosis complex (TSC) patients with epilepsy. METHODS: All patients with epilepsy were selected from Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis (ESOSPIT) project...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Qian, Wang, Yang-Yang, Wang, Qiu-Hong, Tang, Li-Na, Yang, Xiao-Yan, Dun, Shuo, Zou, Li-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: British Epilepsy Association. Published by Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110005/
https://www.ncbi.nlm.nih.gov/pubmed/35605444
http://dx.doi.org/10.1016/j.seizure.2022.05.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110005/
https://www.ncbi.nlm.nih.gov/pubmed/35605444
http://dx.doi.org/10.1016/j.seizure.2022.05.010

Ejemplares similares